Coave Therapeutics
Marie-Anne Burlot is a seasoned professional in the fields of in vivo and translational sciences, currently serving as Director at Coave Therapeutics since 2021, following a role as Project Manager at Medday Pharmaceuticals from 2016 to 2020, where responsibilities included managing preclinical studies, budget oversight, and regulatory document drafting. Previous experience includes serving as Scientific Director at ANIMALLIANCE and extensive research roles at INSERM, focusing on gene therapy for Alzheimer's disease during a PhD program from 2011 to 2014. Marie-Anne has a robust academic background in veterinary medicine and neuroscience, holding a Doctor of Philosophy degree from Université Paris Cité and a Doctor of Veterinary Medicine from Ecole Nationale Vétérinaire de Toulouse.
This person is not in any offices
Coave Therapeutics
Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.